<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; MannKind Corporation</title>
	<atom:link href="http://www.stockbloghub.com/tag/mannkind-corporation/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(BOBE) Company News for May 11, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/05/11/bobe-company-news-for-may-11-2011-corporate-summary/73828</link>
		<comments>http://www.stockbloghub.com/2011/05/11/bobe-company-news-for-may-11-2011-corporate-summary/73828#comments</comments>
		<pubDate>Wed, 11 May 2011 16:16:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Restaurants]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Bob Evans Farms Inc.]]></category>
		<category><![CDATA[BOBE]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Chesapeake Utilities Corporation]]></category>
		<category><![CDATA[Cisco Systems]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[Cosan Limited]]></category>
		<category><![CDATA[CPK]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[CSCO]]></category>
		<category><![CDATA[CZZ]]></category>
		<category><![CDATA[Dean Foods Company]]></category>
		<category><![CDATA[DF]]></category>
		<category><![CDATA[DHX]]></category>
		<category><![CDATA[Dice Holdings Inc]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GPK]]></category>
		<category><![CDATA[Graphic Packaging Holding Company]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[NGLS]]></category>
		<category><![CDATA[PANL]]></category>
		<category><![CDATA[Targa Resources Partners LP]]></category>
		<category><![CDATA[Universal Display Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73828</guid>
		<description><![CDATA[•    Microsoft Corp. (NASDAQ:MSFT) will purchase internet communications leader Skype from the investor consortium led by Silver Lake. The deal which is worth $8.5 billion in cash has been approved by the boards of directors of both companies •    Dean Foods (NYSE:DF) reported Q1 EPS of $0.14, surpassing the Zacks Consensus Estimate of $0.06 per share •    Medical-device maker Boston Scientific Corporation (NYSE:BSX) announced that Ray Elliott would retire as president and CEO at the end of the year •    Shares of online technology-jobs sites operator DICE HOLDINGS, INC. (NYSE:DHX) dropped 5.5% a day after the company revealed that “certain stockholders” would sell 8 million shares. •    Share prices of MannKind Corp.(NASDAQ:MNKD) plunged 12.3% a day after the biotechnology firm  reported a first-quarter loss exceeding expectations •    Late on Monday, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/11/bobe-company-news-for-may-11-2011-corporate-summary/73828/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MNKD) MannKind Corporation’s Afrezza Drug Gets Good News</title>
		<link>http://www.stockbloghub.com/2011/04/13/mnkd-mannkind-corporation%e2%80%99s-afrezza-drug-gets-good-news/71468</link>
		<comments>http://www.stockbloghub.com/2011/04/13/mnkd-mannkind-corporation%e2%80%99s-afrezza-drug-gets-good-news/71468#comments</comments>
		<pubDate>Thu, 14 Apr 2011 02:25:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71468</guid>
		<description><![CDATA[There was some good news for MannKind Corporation’s (MNKD) lead pipeline candidate, Afrezza, when the US Food and Drug Administration (FDA) rescheduled its end-of-review meeting with the company to discuss the candidate. A few days ago, the FDA cancelled the meeting, originally scheduled for April 15, 2011, fearing a potential federal government shutdown in the US. The US regulatory body will now hold the meeting on May 4, 2011. Mannkind has been looking forward to a meeting with the FDA ever since the US regulatory body issued a complete response letter (CRL) in January 2011, for Afrezza. Afrezza is an inhaled insulin for adults suffering from type I or type II diabetes. Afrezza utilizes MannKind’s proprietary dry powder Technosphere formulation of insulin. It is inhaled deep into the lungs using ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/mnkd-mannkind-corporation%e2%80%99s-afrezza-drug-gets-good-news/71468/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MNKD) Why Phase II is the Sweet Spot for Biotech Investing</title>
		<link>http://www.stockbloghub.com/2011/04/13/mnkd-why-phase-ii-is-the-sweet-spot-for-biotech-investing/71385</link>
		<comments>http://www.stockbloghub.com/2011/04/13/mnkd-why-phase-ii-is-the-sweet-spot-for-biotech-investing/71385#comments</comments>
		<pubDate>Wed, 13 Apr 2011 16:23:10 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEL-SCI Corporation]]></category>
		<category><![CDATA[CVM]]></category>
		<category><![CDATA[DCTH]]></category>
		<category><![CDATA[Delcath Systems Inc.]]></category>
		<category><![CDATA[Electro-optical Sciences Inc]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[MELA]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71385</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U’s Healthcare Expert Wednesday, April 13, 2011: Issue #1490 I recently received a call from an investor relations representative who wanted to know if I’d be interested in hearing about a small biotech company with a drug candidate in Phase II trials. Would Rory McIlroy have liked a do-over on Sunday at Augusta? Phase II trials are my favorite time to get involved in a biotech company. I’ll explain why in a moment. But first, a quick review of the phases of clinical trials… The Three Distinct Phases of Clinical Trials Before a new, experimental drug is tried in humans, it’s put to work in test tubes and then animals. Once it’s ready for human trials, it’s tested in three distinct phases. The Phase I trial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/mnkd-why-phase-ii-is-the-sweet-spot-for-biotech-investing/71385/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharmaceutical Industry Outlook &#8211; March 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917</link>
		<comments>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917#comments</comments>
		<pubDate>Thu, 03 Mar 2011 01:14:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67917</guid>
		<description><![CDATA[The pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition, including Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. These products generated more than $15 billion in sales in 2010. The effect of the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MNKD) MannKind Fourth Quarter Reports Smaller-than-Anticipated Loss</title>
		<link>http://www.stockbloghub.com/2011/02/14/mnkd-mannkind-fourth-quarter-reports-smaller-than-anticipated-loss/66858</link>
		<comments>http://www.stockbloghub.com/2011/02/14/mnkd-mannkind-fourth-quarter-reports-smaller-than-anticipated-loss/66858#comments</comments>
		<pubDate>Mon, 14 Feb 2011 20:30:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=66858</guid>
		<description><![CDATA[MannKind Corporation’s (MNKD) fourth quarter 2010 net loss of $0.33 per share was narrower than the Zacks Consensus Estimate of a loss of $0.40. The company had suffered a loss of $0.41 (excluding the loss of $12.8 million pertaining to the disposal of fixed assets) in the year-ago quarter. The narrower loss was attributable to lower expenses incurred in the reported quarter on the inhaled insulin candidate Afrezza. The candidate is being developed for treating type I and type II diabetes. MannKind failed to generate any revenues in the reported quarter as in the year-ago period. Reported operating expenses slipped 42.5% to $32.1 million in the reported quarter. Research and development (R&#38;D) spend in the quarter declined 44% to $24.2 million. The reduction was attributable to the reduced spending on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/14/mnkd-mannkind-fourth-quarter-reports-smaller-than-anticipated-loss/66858/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AKS) Stock Market News for December 29, 2010 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2010/12/29/aks-stock-market-news-for-december-29-2010-market-news/64025</link>
		<comments>http://www.stockbloghub.com/2010/12/29/aks-stock-market-news-for-december-29-2010-market-news/64025#comments</comments>
		<pubDate>Wed, 29 Dec 2010 23:52:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Steel & Iron]]></category>
		<category><![CDATA[AK Steel Holding Corporation]]></category>
		<category><![CDATA[AKS]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[Exxon Mobil Corporation]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[NEM]]></category>
		<category><![CDATA[Newmont Mining Corporation]]></category>
		<category><![CDATA[TIE]]></category>
		<category><![CDATA[Titanium Metals Corporation]]></category>
		<category><![CDATA[XOM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=64025</guid>
		<description><![CDATA[After-effects from the blizzard which had hit the northeast continued as trading volumes remained thin for the second consecutive day and markets closed mixed on Tuesday. Oil prices and energy stocks, nonetheless, moved up primarily due to the blizzard. The Dow Jones Industrial Average was up 0.18% and closed at 11,575. The S&#38;P 500 rose 0.08% to close at 1,258 and the Nasdaq was down 0.16% to end the day at 2,662. The CBOE Volatility Index (VIX) ended marginally lower by 0.85% to close at 17.52. On the New York Stock Exchange, breadth of the market was negatively biased as 1543 stocks declined and 1440 stocks ended in the green. Trading volumes were on the lighter side. The day was also marred by some economic data that fell short of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/29/aks-stock-market-news-for-december-29-2010-market-news/64025/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MNKD) MannKind Corporation Analyst Maintains Neutral Rating on Stock</title>
		<link>http://www.stockbloghub.com/2010/09/11/mnkd-mannkind-corporation-analyst-maintains-neutral-rating-on-stock/51070</link>
		<comments>http://www.stockbloghub.com/2010/09/11/mnkd-mannkind-corporation-analyst-maintains-neutral-rating-on-stock/51070#comments</comments>
		<pubDate>Sun, 12 Sep 2010 04:33:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MNKD]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=51070</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on MannKind Corporation (MNKD) with a target price of $6.25. MannKind is a Valencia, California-based biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diabetes, cancer and inflammatory and autoimmune diseases. The company’s lead pipeline candidate, Afrezza, is inhaled insulin for the treatment of type I and type II diabetes. MannKind filed a New Drug Application (NDA) for Afrezza with the US Food and Drug Administration (FDA) in March 2009. However, the agency issued a complete response letter (CRL) asking for additional information in addition to updated safety data. MannKind subsequently submitted a response to the CRL. The regulatory body classified the response as a class II resubmission. The resubmission included safety and efficacy data from recently completed studies on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/11/mnkd-mannkind-corporation-analyst-maintains-neutral-rating-on-stock/51070/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MNKD) MannKind Gets Good News From FDA</title>
		<link>http://www.stockbloghub.com/2010/07/24/mnkd-mannkind-gets-good-news-from-fda/44502</link>
		<comments>http://www.stockbloghub.com/2010/07/24/mnkd-mannkind-gets-good-news-from-fda/44502#comments</comments>
		<pubDate>Sat, 24 Jul 2010 15:21:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MNKD]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44502</guid>
		<description><![CDATA[MannKind Corporation (MNKD) received a boost when the US Food and Drug Administration (FDA) accepted MannKind’s response to the complete response letter (CRL) issued by the agency on its inhaled insulin candidate, Afrezza. The candidate is being developed for treating type I and type II diabetes. The agency informed the company that the resubmission will be treated as a class II review. Consequently, a decision from the FDA should be out within 6 months (target date: December 29, 2010). The resubmission included safety and efficacy data from recently completed studies on the candidate. We remind investors that the FDA had issued a CRL earlier in the year to MannKind in response to the New Drug Application (NDA) submitted in 2009 for Afrezza. The FDA asked MannKind for certain additional information ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/24/mnkd-mannkind-gets-good-news-from-fda/44502/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma &amp; Biotech Stock Review &#8211; April 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472</link>
		<comments>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472#comments</comments>
		<pubDate>Thu, 29 Apr 2010 14:10:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MIL]]></category>
		<category><![CDATA[Millipore Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35472</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MNKD) MannKind Suffers Setback From FDA</title>
		<link>http://www.stockbloghub.com/2010/03/16/mnkd-mannkind-suffers-setback-from-fda/30773</link>
		<comments>http://www.stockbloghub.com/2010/03/16/mnkd-mannkind-suffers-setback-from-fda/30773#comments</comments>
		<pubDate>Tue, 16 Mar 2010 22:46:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MNKD]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30773</guid>
		<description><![CDATA[MannKind Corp. (MNKD) suffered a major setback with respect to its lead product, Afrezza, inhaled insulin for treating type I and type II diabetes. The company received a complete response letter (CRL) from the US Food &#38; Drug Administration (FDA) recently. The FDA has asked MannKind for certain additional information and clinical data that has been submitted along with the New Drug Application (NDA). The agency has also asked for information about the commercial version of the company’s MedTone inhaler, which is different from the one used during clinical trials. Although additional clinical studies are not required at present, the FDA has asked for updated safety data. Changes to the proposed labeling of the cartridges, foil pouches and cartons used in the device have been requested. To sort out the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/16/mnkd-mannkind-suffers-setback-from-fda/30773/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MNKD) MannKind Narrows Fourth Quarter Loss</title>
		<link>http://www.stockbloghub.com/2010/02/02/mnkd-mannkind-narrows-fourth-quarter-loss/26822</link>
		<comments>http://www.stockbloghub.com/2010/02/02/mnkd-mannkind-narrows-fourth-quarter-loss/26822#comments</comments>
		<pubDate>Wed, 03 Feb 2010 01:20:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MNKD]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26822</guid>
		<description><![CDATA[During the fourth quarter of 2009, MannKind (MNKD) lowered its loss per share to 53 cents compared to a loss of 82 cents in the year-ago period. However, the loss per share missed the Zacks Consensus Estimate of 41 cents. For the full year, MannKind reported a loss per share of $2.07, better than $2.98 in 2008. The company does not have any marketed products, and hence does not generate any revenues. Afrezza (formerly known as Afresa) &#8212; inhaled insulin for the treatment of type I and type II diabetes, MNKD&#8217;s lead pipeline candidate &#8212; is currently under US Food and Drug Administration (FDA) review. The primary reason behind the lower loss was a 32% year-over-year decline in operating expenses which came in at $55.8 million. While general and administrative ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/02/mnkd-mannkind-narrows-fourth-quarter-loss/26822/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DNDN) These Biotech Stocks Are Just What the Doctor Ordered</title>
		<link>http://www.stockbloghub.com/2010/01/29/dndn-these-biotech-stocks-are-just-what-the-doctor-ordered/26383</link>
		<comments>http://www.stockbloghub.com/2010/01/29/dndn-these-biotech-stocks-are-just-what-the-doctor-ordered/26383#comments</comments>
		<pubDate>Sat, 30 Jan 2010 00:47:12 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[Generex Biotechnology Corporation]]></category>
		<category><![CDATA[GNBT]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MNKD]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26383</guid>
		<description><![CDATA[by Louise Harris, Investment U Research Thursday, January 28, 2010 They say that one in every nine women will get breast cancer. It’s a staggering statistic, just like the equally frightening claim that one in four people will end up with some type of cancer in their lifetimes… or that the disease affects 10 million people around the globe every year. Fortunately, doctors, research teams and entire corporations have set their brilliant minds to finding a viable cure. And they’ve made enormous strides in DNA profiling and the emerging field of pharmacogenomics – which studies how individual genetics affect medication outcomes. Meanwhile, other companies are developing prophylactic vaccines, which target viruses that lead to cancer. Kalorama Information expects the market to double from the $2 billion recorded in 2008 to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/29/dndn-these-biotech-stocks-are-just-what-the-doctor-ordered/26383/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) Pharma &amp; Biotech Stock Review &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385</link>
		<comments>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385#comments</comments>
		<pubDate>Sat, 30 Jan 2010 00:08:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RX]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26385</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MNKD) MannKind Corporation Gets FDA Setback</title>
		<link>http://www.stockbloghub.com/2010/01/11/mnkd-mannkind-corporation-gets-fda-setback/24632</link>
		<comments>http://www.stockbloghub.com/2010/01/11/mnkd-mannkind-corporation-gets-fda-setback/24632#comments</comments>
		<pubDate>Mon, 11 Jan 2010 22:29:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24632</guid>
		<description><![CDATA[Recently, MannKind Corporation (MNKD) received a setback regarding the approval of its much awaited product Afrezza (formerly known as Afresa) ? inhaled insulin for the treatment of type I and type II diabetes. While the original Prescription Drug User Fee Act (PDUFA) date was January 16, 2010, the US Food and Drug Administration (FDA) informed MannKind that they will not be able to review the new drug application (NDA) within the time frame since they are yet to complete the inspection of the insulin manufacturing facilities of N.V. Organon, a third-party supplier to MannKind. The delay comes as a big setback for the company as it has been banking heavily on the approval of Afrezza. Moreover, MannKind has received no intimation about the expected date of the approval. However, discussions ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/11/mnkd-mannkind-corporation-gets-fda-setback/24632/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MNKD) MannKind Awaits US Food and Drug Administration Decision</title>
		<link>http://www.stockbloghub.com/2010/01/06/mnkd-mannkind-awaits-us-food-and-drug-administration-decision/24338</link>
		<comments>http://www.stockbloghub.com/2010/01/06/mnkd-mannkind-awaits-us-food-and-drug-administration-decision/24338#comments</comments>
		<pubDate>Wed, 06 Jan 2010 23:57:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24338</guid>
		<description><![CDATA[The next few days will be very crucial for MannKind (MNKD). The US Food and Drug Administration (FDA) is expected to decide on the company’s lead product candidate Afresa, which is an inhaled insulin for the treatment of type I and type II diabetes, within January 16, 2010. We believe that Afresa offers distinct advantages over traditional needle-based insulin therapy, which currently dominates the market. The key advantage is the convenience of an inhaled delivery. However, the path to approval is not easy since many large pharmaceutical companies in the past have made unsuccessful attempts to bring such a product into the market. Back in 2006, Pfizer’s (PFE) Exubera was the first FDA approved inhaled insulin which later on failed miserably. Pfizer witnessed another major blow with the occurrence of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/06/mnkd-mannkind-awaits-us-food-and-drug-administration-decision/24338/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) Big Pharma and Biotech &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146</link>
		<comments>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146#comments</comments>
		<pubDate>Mon, 09 Nov 2009 23:57:38 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RX]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as the products losing patent protection have. With most of the big pharma companies already facing patent challenges for their ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MNKD) MannKind Pharma Beats &#8211; Awaiting FDA Review</title>
		<link>http://www.stockbloghub.com/2009/11/04/mnkd-mannkind-pharma-beats-awaiting-fda-review/19581</link>
		<comments>http://www.stockbloghub.com/2009/11/04/mnkd-mannkind-pharma-beats-awaiting-fda-review/19581#comments</comments>
		<pubDate>Thu, 05 Nov 2009 00:46:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MNKD]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19581</guid>
		<description><![CDATA[MannKind Pharma’s (MNKD) third quarter loss per share came in at 42 cents, better than the Zacks Consensus Estimate of 49 cents and loss of 67 cents reported in the year-ago period. The company does not have any revenue stream at present &#8212; its lead product, Afresa (inhaled insulin for the treatment of type I and type II diabetes) is currently under US Food and Drug Administration (FDA) review. MannKind filed a New Drug Application (NDA) for Afresa with the FDA in March 2009, which was subsequently accepted in May 2009. The company has been assigned a Prescription Drug User Fee Act (PDUFA) date of January 16, 2010. Operating expenses for the third quarter declined 38% to $42.8 million, primarily due to a huge reduction in R&#38;D expenses. Reduced costs ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/04/mnkd-mannkind-pharma-beats-awaiting-fda-review/19581/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

